N/A
Completed N=42
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors
Source: ClinicalTrials.gov NCT03109262 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Sep 2021
Primary outcomePrimary: Image Quality for 90-Y PET/CT Scans — 3.56; 4.63; 4.89; 4.93 units on a scale
Summary
This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors . Images produced by PET/CT may provide better information about the distribution of particles, such as Y90 glass microspheres, delivered for selective internal radiation therapy (SIRT) as compared to regular medical care images useing technetium Tc-99m albumin-aggregated single photon emission computed tomography (SPECT)/CT images.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Image Quality for 90-Y PET/CT Scans |
3.56; 4.63; 4.89; 4.93 | — |
| SECONDARY Radiopharmaceutical Dosimetry Accuracy for 90-Y PET/CT Scans and 99mTc-MAA SPECT/CT Scans |
142.9; 118.9 | — |
Eligibility Criteria
Inclusion Criteria
- Patient provides written informed consent
- Patient is referred for 90Y SIRT radioembolization of liver tumor(s)
- Patient is capable of complying with study procedures
- Patient is able to remain still for duration of imaging procedure (approximately 30 minutes total for digital PET/CT)
Exclusion Criteria
- Patient is pregnant or nursing
Data sourced from ClinicalTrials.gov (NCT03109262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.